A citation-based method for searching scientific literature

Edmund Lee, William L Trepicchio, Judith L Oestreicher, Debra Pittman, Frank Wang, Francesca Chamian, Madhav Dhodapkar, James G Krueger. J Exp Med 2004
Times Cited: 660



Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson, Enrique Rivas, Tsen-Fang Tsai, Norman Wasel, Stephen Tyring, Thomas Salko, Isabelle Hampele, Marianne Notter, Alexander Karpov, Silvia Helou, Charis Papavassilis. N Engl J Med 2014
Times Cited: 1228




List of shared articles



Times cited

Regulation of IL-17A-Producing Cells in Skin Inflammatory Disorders.
Pushpa Pandiyan, Thomas S McCormick. J Invest Dermatol 2022
2

Update on the etiopathogenesis of psoriasis (Review).
Daciana Elena Branisteanu, Catalina Cojocaru, Roxana Diaconu, Elena Andrese Porumb, Anisia Iuliana Alexa, Alin Codrut Nicolescu, Ilarie Brihan, Camelia Margareta Bogdanici, George Branisteanu, Andreea Dimitriu,[...]. Exp Ther Med 2022
2

Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action.
Aina Akmal Mohd Noor, Maryam Azlan, Norhanani Mohd Redzwan. Biomedicines 2022
0

Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached?
Gangadhar Hari, Anoop Kishore, Sreedhara Ranganath Pai Karkala. Eur J Pharmacol 2022
0

Galectin-8 Is Upregulated in Keratinocytes by IL-17A and Promotes Proliferation by Regulating Mitosis in Psoriasis.
Yuan-Hsin Lo, Chi-Shan Li, Hung-Lin Chen, Cho-Ying Chiang, Chi-Chun Huang, Ting-Jui Tu, Tzu-Han Lo, David F Choy, Joseph R Arron, Huan-Yuan Chen,[...]. J Invest Dermatol 2021
1

Psoriasis: Recent progress in molecular-targeted therapies.
Masaru Honma, Kei Hayashi. J Dermatol 2021
14

Pathophysiology of psoriasis: A review.
Keiichi Yamanaka, Osamu Yamamoto, Tetsuya Honda. J Dermatol 2021
13


From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment.
Silvia Vidal, Lluís Puig, José-Manuel Carrascosa-Carrillo, Álvaro González-Cantero, José-Carlos Ruiz-Carrascosa, Antonio-Manuel Velasco-Pastor. Int J Mol Sci 2021
4

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab.
Feras M Ghazawi, Farhan Mahmood, Leon Kircik, Yves Poulin, Marc Bourcier, Ronald Vender, Marni C Wiseman, Charles Lynde, Ivan V Litvinov. Front Med (Lausanne) 2021
4

Anti-Psoriatic Effects of Antimony Compounds In Vitro.
Fabian Gendrisch, Birgit Haarhaus, Christoph M Schempp, Ute Wölfle. Molecules 2021
0

An Analysis of IL-10, IL-17A, IL-17RA, IL-23A and IL-23R Expression and Their Correlation with Clinical Course in Patients with Psoriasis.
Magdalena Kutwin, Monika Migdalska-Sęk, Ewa Brzeziańska-Lasota, Piotr Zelga, Anna Woźniacka. J Clin Med 2021
0

Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities.
Alan Menter, Gerald G Krueger, So Yeon Paek, Dario Kivelevitch, Iannis E Adamopoulos, Richard G Langley. Dermatol Ther (Heidelb) 2021
7

Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.
Kamran Ghoreschi, Anna Balato, Charlotta Enerbäck, Robert Sabat. Lancet 2021
53

Biologics for chronic inflammatory skin diseases: an update for the clinician.
Yiqiu Yao, Astrid-Helene Ravn Jørgensen, Simon Francis Thomsen. J Dermatolog Treat 2020
11

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
Wendy Li, Rima Ghamrawi, Wasim Haidari, Steven R Feldman. Ann Pharmacother 2020
4

Current Developments in the Immunology of Psoriasis.
Franziska Grän, Andreas Kerstan, Edgar Serfling, Matthias Goebeler, Khalid Muhammad. Yale J Biol Med 2020
44

Role of Innate Immune Cells in Psoriasis.
Yuki Sato, Eisaku Ogawa, Ryuhei Okuyama. Int J Mol Sci 2020
16


Interleukin-17A and Keratinocytes in Psoriasis.
Masutaka Furue, Kazuhisa Furue, Gaku Tsuji, Takeshi Nakahara. Int J Mol Sci 2020
60

Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
A Al-Janabi, Z K Jabbar-Lopez, C E M Griffiths, Z Z N Yiu. Br J Dermatol 2019
6

Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.
K Reich, P Rich, C Maari, R Bissonnette, C Leonardi, A Menter, A Igarashi, P Klekotka, D Patel, J Li,[...]. Br J Dermatol 2019
43